Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367820 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
A Phase 3 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 638
- Enrollment target
NCT02367820 is a Phase 3 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 638 participants.
The verdict
NCT02367820, a Phase 3 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 638 participants
- Enrollment target
Study Summary
The purpose of this 52-week open label study is to determine the long-term safety of a new opioid molecule, NKTR-181, in patients with moderate to severe chronic low back pain or chronic non-cancer pain.
Interventions
- DRUG NKTR-181 BID tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 638 participants |
| Start Date | 2015-04-14 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02367820
The ClinicalTrials.gov registry entry for NCT02367820 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 638 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NKTR-181 BID tablets is the first listed.
NCT02367820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02367820 about?
NCT02367820 is a clinical study titled "Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain". The purpose of this 52-week open label study is to determine the long-term safety of a new opioid molecule, NKTR-181, in patients with moderate to severe chronic low back pain or chronic non-cancer pain.
What is the current status of trial NCT02367820?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 638 participants. The study started on 2015-04-14. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02367820?
The interventions under investigation include: NKTR-181 BID tablets (DRUG).
Who is sponsoring clinical trial NCT02367820?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.